Levamisole


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Ascariasis 150 mg as a single dose. Ancylostomiasis; Mixed-ascariasis hookworm infections 2.5 mg/kg as a single dose, repeat after 7 days for severe cases.
Dosage Details
Oral
Ascariasis
Adult: 150 mg as a single dose.
Child: 3 mg/kg as a single dose.

Oral
Ancylostomiasis, Mixed ascariasis-hookworm infections
Adult: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases.
Child: 2.5 mg/kg as a single dose, repeated after 7 days in severe cases.
Administration
Should be taken with food. Take w/ meals to minimise side effects eg, nausea.
Contraindications
Preexisting blood disorders; pregnancy and lactation; rheumatoid arthritis; severe renal impairment.
Special Precautions
Hepatic impairment, Sjogren's syndrome.
Adverse Reactions
Nausea, vomiting, diarrhoea, abdominal pain, dizziness and headache. Fever, influenza-like syndrome, arthralgia, muscle pain, rash, taste disturbances and cutaneous vasculitis.
Potentially Fatal: Agranulocytosis, leucopenia, thrombocytopenia.
Drug Interactions
May increase toxicity of phenytoin. Increases bioavailability of ivermectin; decreases bioavailability of albendazole. Alcohol causes disulfiram-like reaction.
Action
Description: Levamisole is the active laevo-isomer of tetramisole. It works by paralysing susceptible intestinal worms which are then excreted from the intestines. Levamisole also enhances cellular immune responses in humans.
Pharmacokinetics:
Absorption: Well-absorbed from the GI tract. Peak plasma concentrations are achieved in 1.5-2 hr.
Metabolism: Occurs extensively in the liver.
Excretion: Mainly in the urine (70% as metabolites and 5% as unchanged drug) and small amounts in the faeces.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Levamisole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in